Amber Reinecke, PA
Medical · Cushing, OKNPI 1679962856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,101 and has fallen 59.1% since, to $451 in 2025.
Across 187 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$773
- Astellas Pharma US Inc$520
- AbbVie$333
- GSK$293
- Regeneron Healthcare Solutions, Inc.$225
- Lilly USA, LLC$224
- plus $978 from 24 others
What the payments were for
- Food & beverage$3,347100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $773 |
| Astellas Pharma US Inc | 23 | $520 |
| AbbVie | 32 | $333 |
| GSK | 15 | $293 |
| Regeneron Healthcare Solutions, Inc. | 9 | $225 |
| Lilly USA, LLC | 13 | $224 |
| Mylan Specialty L.p. | 8 | $159 |
| Boehringer Ingelheim | 10 | $143 |
| Exact Sciences | 5 | $112 |
| Novo Nordisk | 3 | $55 |
| Pfizer | 4 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Johnson & Johnson | 3 | $37 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Merck | 2 | $33 |
| Novartis | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Amgen | 1 | $21 |
| Organon | 2 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Bayer | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| Corium, LLC | 1 | $11 |
How this compares
$3,347 in reported general payments places this provider in the 80th percentile of 370 medical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 62 | $60,641 |
| MounjaroTirzepatide | 36 | $45,830 |
| OzempicSemaglutide | 34 | $34,060 |
| FarxigaDapagliflozin Propanediol | 22 | $29,361 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $25,676 |
| EliquisApixaban | 28 | $21,708 |
| XareltoRivaroxaban | 21 | $20,957 |
| JardianceEmpagliflozin | 22 | $20,569 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $17,811 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $8,835 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $6,181 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $5,905 |
| MyrbetriqMirabegron | 12 | $5,422 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,331 |
| Pregabalin | 24 | $2,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $224 | $106,47198 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $773 | $55,03747 claims |
| Novo NordiskOzempic | $55 | $34,06034 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $143 | $26,75033 claims |
| PfizerEliquis | $54 | $21,70828 claims |
| Johnson & JohnsonXarelto | $37 | $20,95721 claims |
| Astellas Pharma US IncMyrbetriq | $520 | $5,42212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 370 medical providers in Oklahoma.
Other medical in Cushing
- Lisa NoeCushing$8K
- Mebin ThomasOklahoma City$323K
- Kelle ChristiansonMidwest City$117K
- Kristine MurrowOklahoma City$81K
- Matthew DohlmanTulsa$39K
- Katelyn PuryearOklahoma City$22K
- Tara LinvilleTulsa$19K
- Debra OdomTulsa$17K
- Donna BowersTuttle$16K
- Kelly WalworthOklahoma City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.